# China's booming biotech, from a brain implant to drug discovery

An episode of [Science Friday](https://invisiblenetwork.ai/podcast/73329284), 13 Jul 2026, 18 min.

Audio: https://pscrb.fm/rss/p/mgln.ai/e/14/pdst.fm/e/dts.podtrac.com/pts/redirect.mp3/waaa.wnyc.org/ac8e2039-dfef-4938-b66a-c2f58f4b7599/episodes/599d35e4-cfb1-40fb-b718-0ac5e17d1919/audio/128/default.mp3?aid=rss_feed&awCollectionId=ac8e2039-dfef-4938-b66a-c2f58f4b7599&awEpisodeId=599d35e4-cfb1-40fb-b718-0ac5e17d1919&feed=h18ZIZD_

In March, China became the first country to approve an invasive brain-computer interface beyond clinical trials. The implant, called NEO, is now available to some patients with limb paralysis due to a spinal cord injury. Ira talks with Wired staff writer Emily Mullin about the significance of this milestone. Plus, brain implants aren’t the only development: China’s entire biotech industry has skyrocketed in recent years. A decade ago, about 8% of new drug molecules were discovered in China. Now it's over 40%. And more clinical trials are now being conducted there than in the U.S. or Europe. Ira talks with health policy researcher So-Yeon Kang, who’s been following the Chinese pharma industry’s meteoric rise. Guests: Emily Mullin is a staff writer at Wired. Dr. So-Yeon Kang is an Assistant Professor of Health Management and Policy at Georgetown University. Other episodes you may enjoy: • Advances In Brain-Computer Interfaces For People With Paralysis • How China Is Driving Down Electricity Costs With Renewables Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow us on socials @ scifri on YouTube, Instagram, Facebook, TikTok, and Bluesky and sign up for our newsletters. Got a science question that’s keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them.